Αποτελέσματα αναζήτησης - "иммунологические нарушения"

1

Academic Journal

ИММУНОЛОГИЧЕСКАЯ ДИАГНОСТИКА И ПРОГНОЗИРОВАНИЕ ТЕЧЕНИЯ РАКА ПАРЕНХИМЫ ПОЧКИ (ЛИТЕРАТУРНЫЙ ОБЗОР)

Συγγραφείς: Александр Александрович Кривобок, Александр Игоревич Колганов, Турал Магирович Мурадов

Πηγή: Российские биомедицинские исследования, Vol 10, Iss 2 (2025)

Θεματικοί όροι: иммунологическая диагностика, опухоль паренхимы почки, иммунологические нарушения, противоопухолевая иммунологическая толерантность, Т-лимфоциты, микроокружение опухоли, Medicine (General), R5-920

Περιγραφή αρχείου: electronic resource

Relation: https://ojs3.gpmu.org/index.php/biomedical-research/article/view/6535; https://doaj.org/toc/2658-6584; https://doaj.org/toc/2658-6576

Σύνδεσμος πρόσβασης: https://doaj.org/article/2239b39dff8f44e0afd1e2571c3edc79

View record in DOAJ

2

Academic Journal

Атопический дерматит (обзор литературы) ; Atopicheskii dermatit (obzor literatury)

Συγγραφείς: Прибылова Нина Сергеевна, ФГБОУ ВО «Ульяновский государственный педагогический университет им. И.Н. Ульянова», Nina S. Pribylova, Ulyanovsk State Pedagogical University named after I. N. Ulyanov, Антонова Елена Ивановна, Научно-исследовательский центр фундаментальных и прикладных проблем биоэкологии и биотехнологии ФГБОУ ВО «Ульяновский государственный педагогический университет им. И.Н. Ульянова», Elena I. Antonova, Nauchno-issledovatel'skii tsentr fundamental'nykh i prikladnykh problem bioekologii i biotekhnologii FGBOU VO "Ul'ianovskii gosudarstvennyi pedagogicheskii universitet im. I.N. Ul'ianova"

Πηγή: Fundamental and applied research for key propriety areas of bioecology and biotechnology; 137-146 ; Фундаментальные и прикладные исследования по приоритетным направлениям биоэкологии и биотехнологии; 137-146

Θεματικοί όροι: микробиом, патогенез, атопический дерматит, аллергические заболевания, генетические нарушения, дефекты эпидермального барьера, иммунологические нарушения

Περιγραφή αρχείου: text/html

Relation: info:eu-repo/semantics/altIdentifier/isbn/978-5-907830-38-7; https://phsreda.com/e-articles/10590/Action10590-112050.pdf; Березина А.С. Атопический дерматит. Особенности патогенеза, клиники, диагностики / А.С. Березина, Ю.В. Карачева, Ю.Ю. Винник [и др.] // Вестник СурГУ. Медицина. – 2023. – Т. 16. №2. – С. 8–13. – DOI 10.35266/2304-9448-2023-2-8-13. – EDN ZLLJEY; Зимнуров А.Р. Уровень иммуноглобулинов в периферической крови у детей различной возрастной группы с клиническим диагнозом атопический дерматит / А.Р. Зимнуров, С.Д. Рашитова, Л.Н. Цвилик [и др.] // Сборник материалов VI Всероссийской научно-практической конференции с международным участием Фундаментальные и прикладные исследования по приоритетным направлениям биоэкологии и биотехнологии. – 2023. – С. 183–190. – DOI 10.31483/r-107056. – EDN KDDZFR; Карамова А.Е. Оценка тяжести атопического дерматита – SCORAD и EASI / А.Е. Карамова, В.В. Чикин, Л.Ф. Знаменская [и др.] // Вестник дерматологии и венерологии. – 2022. – №98 (3). – С. 53–60. – DOI 10.25208/vdv1335. – EDN MLAJRU; Клинические рекомендации. Атопический дерматит [Электронный ресурс]. – Режим доступа: https://cr.minzdrav.gov.ru/schema/265_2 (дата обращения: 17.07.2023).; Мирзоян В.Л. Атопический дерматит. Алгоритмы диагностики и лечения: учебное пособие / В.Л. Мирзоян, К.И. Разнатовский, К.Н. Монахов. – СПб.: Изд-во СЗГМУ им. И.И. Мечникова, 2018. – 64 с.; Bousquet J., Van Cauwenberg P., Khaltaev N. Ariya Seminar G and World Health O. Allergic rhinitis and its impact on asthma // J. Allergy Clinic. Immunol. 108, S147-S334 (2001). EDN LSGMGL; Chen H., Common J.E., Haynes R.L., Balakrishnan A., Brown S.J., Guo K.S., Cordell H.J., Sandilands A., Campbell L.E., Krobot K. [et al.] Wide range of filaggrin null mutations in atopic dermatitis highlights differences between Singaporean Chinese and European populations. Br. J. Dermatol. 2011.; Dharmaj S.S., Martin P.E., Osborne N.J., Coplin J.J., Gurrin L.K., Ponsonby A., Tan M.L., Matheson M.K., Low A.J.J., Dang T. [et al.] Epidemiology of food sensitization-associated eczema in infants in the population-based HealthNuts study. J. Allergy Clinic. Immunol. 2011.; Chintraja R.S., Hernandez J.D., Boyd S.D., Galli S.J. and Nado K.K. Molecular and cellular mechanisms of food allergy and food tolerance. J. Allergy Clinic. Immunol. 137, 984–997 (2016).; Chintraja R.S. [et al.] Diagnosis of food allergies. Pediatrician. Wedge. North Am. 62, 1393–1408 (2015).; Coplin J.J., Peters R.L., Ponsonby A.L., Gurrin L.S., Hill D., Tan M.L.K., Dharmaj S.S., Allen K.J., HealthNuts Research Group. Increased risk of peanut allergy in infants of Asian parents compared with children of Australian parents. Allergy. 2014; Dechildre A. and Lejeune S. How to cope with food allergy symptoms? Well. Opinion. Allergy clinic. Immunol. 18, 234–242 (2018).; Dong W.L. [et al.] Prevalence and years lived with disability due to atopic dermatitis in China: results from the 2019 Global Burden of Disease Study.; Feld M. [et al.] The itch- and TH2-related cytokine IL-31 promotes sensory nerve growth. J. Allergy Clinic. Immunol. 138, 500–508 e524 (2016).; Patrick G.J., Archer N.K., Miller L.S. Which Way Are We Going? Complex interactions in the pathogenesis of atopic dermatitis. Jay Invest Dermatol. 2021 February; 141 (2): 274–284. DOI 10.1016/j.jid.2020.07.006. EDN KOVNQA; Higaki S., Morohashi M., Yamagishi T., Hasegawa Y. Comparative study of staphylococci from the skin of patients with atopic dermatitis and healthy subjects. Int. J Dermatol 1999; Hong K.L., Tsang Y.K., Lee W.V.I., Pong N.H., Ha G., Lee S.T. [et al.] Efficacy of sodium hypochlorite (bleach) baths in reducing Staphylococcus aureus colonization in moderate to severe childhood eczema: a randomized, placebo-controlled crossover trial. J. Dermatol. Treat 2016; Hönzke S., Wallmeyer L., Ostrowski A., Radbruch M., Mundchenk L., Schäfer-Korting M. [et al.] Effect of Th2 cytokines on keratinized membrane, tight junction proteins and β-defensins in filaggrin-deficient skin equivalents. J. Invest. Dermatol 2016; Howell M.D., Bohuniewicz M., Pastore S., Novak N., Bieber T., Girolomoni G. [et al.] Mechanism of HBD-3 deficiency in atopic dermatitis. Wedge. Immunol. Orlando, Florida, 2006.; Howell M.D., Fairchild H.R., Kim B.E., Bin L., Boguniewicz M., Redzic J.S. [et al.] Th2 cytokines act on S100/A11 to suppress keratinocyte differentiation. J. Invest. Dermatol 2008.; Howell M.D., Kim B.E., Gao P., Grant A.V., Bohunevich M., DeBenedetto A. [et al.] Cytokine modulation of filaggrin expression in atopic dermatitis skin. J. Allergy Clinic. Immunol 2009.; Huang J.T., Abrams M., Tlugan B., Rademaker A., Paller A.S. Treatment of Staphylococcus aureus colonization in atopic dermatitis reduces the severity of the disease. Pediatrics. 2009.; Hung S.H., Lin Y.T., Chu S.I. [et al.] Staphylococcal colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Allergy. Asthma. Immunol 2007.; Hussain M., Borcard L., Walsh K.P. [et al.] IL-4, derived from basophils, contributes to the sensitization of epicutaneous antigen, which accompanies the development of food allergy. J. Allergy Clinic. Immunol 2018.; Hvid M., Johansen S., Deleran B. [et al.] Regulation of caspase 14 expression in keratinocytes by inflammatory cytokines – a possible link between decreased skin barrier function and inflammation. Exp. Dermatol 2011.; Kattan J.D., Wang J. Allergen testing for food allergies: ready for prime time? Well. Allergy Asthma Report 13, 58–63 (2013).; Kaufman B.P., Guttman-Yassky E., Alexis A. F. Atopic dermatitis in diverse racial and ethnic groups – Variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018; 27 (4): 340–357. DOI 10.1111/exd.13514. EDN QDYHYC; Kim M., Kim Y.M., Lee J.Y. [et al.] Seasonal variations and monthly patterns of skin symptoms in Korean children with atopic syndrome eczema/dermatitis. Allergy Asthma Textbook. 2017; 38 (4).; Lloyd-Lavery A. [et al.] What's new in atopic eczema? Analysis of systematic reviews published in 2016. Part 2: epidemiology, etiology and risk factors. Wedge. Exp. Dermatol 44, 370–375 (2019).; Lo W., Tan M.L.K. Epidemiology of food allergy in a global context. Int J Environ Res Publ Health. 2018.; Lowe A.J., Leung D.Y. M., Tang M.L.K. [et al.] The skin as a target for prevention of the atopic march. Ann Allergy Asthma Immunol. 2018; 120 (2) : 145–151.; Meghji, J., Mortimer C., Jayasuriya S. and Marks G.B. Lung health in low- and middle-income countries: meeting the challenges ahead-the authors' response. Lancet 398, 490 (2021).; Newman K.L., Chater A., Knibb R.K. Beliefs about food allergies in adolescents aged 11–19 years: a systematic review. Klin Transl Allergy. 2022, April 6; 12 (4).; Novak N., Bieber T. The pathogenesis of atopic dermatitis [Electronic resource]. – Access mode: https://www.mitchmedical.us/atopic-dermatitis/the-pathogenesis-of-atopic-dermatitis.html (access date 04.05.2024).; Salikova T.I., Maksimov V.N., Maksimova Yu.V. [et al.] Mutations in the filaggrin gene as a predisposing factor in the development of atopic dermatitis. Clin dermat vener. 2010; 8 (3): 4‑7.; Sroka-Tomaszewska J., Trzeciak M. Molecular mechanisms of the pathogenesis of atopic dermatitis. Int. J. Mol. Sci. 2021, 22.; Tsoi L.S. [et al.] The progression of acute atopic dermatitis to chronic is associated with quantitative, rather than qualitative changes in the cytokine response. J. Allergy Clinic. Immunol. 145, 1406–1415 (2020).; Walsh J., O'Flynn N. Diagnosis and assessment of food allergies in children and young people in primary care and community settings: NICE clinical guidelines // General Practice Br J. 2011; 61(588): 473–5.; Wang J., Zhou Y., Zhang X. [et al.] Pathogenesis of allergic diseases and the significance of therapeutic measures. Sig Transduct Target Ther 8, 138 (2023). DOI 10.1038/s41392-023-01344-4. EDN VSMTGI; Weidinger S., Beck L.A., Bieber T. [et al.] Atopic dermatitis. Nat. Rev. Dis. Note 4, 1 (2018).; https://phsreda.com/article/112050/discussion_platform

Διαθεσιμότητα: https://phsreda.com/article/112050/discussion_platform
https://phsreda.com/files/Books/10590/Cover-10590.jpg?req=112050
https://doi.org/10.31483/r-112050

View record from BASE

3

Academic Journal

Incomplete systemic lupus erythematosus. Own observation and literature review ; Неполная системная красная волчанка. Собственное наблюдение и обзор литературы

Συγγραφείς: T. A. Panafidina, T. V. Popkova, A. M. Lila, E. L. Nasonov, Т. А. Панафидина, Т. В. Попкова, А. М. Лила, Е. Л. Насонов

Συνεισφορές: Настоящее исследование выполнено в рамках фундаментальной темы «Изучение иммунопатологии, диагностики и терапии на ранних стадиях системных ревматических заболеваний» (1021051402790-6).

Πηγή: Rheumatology Science and Practice; Vol 61, No 6 (2023); 678-688 ; Научно-практическая ревматология; Vol 61, No 6 (2023); 678-688 ; 1995-4492 ; 1995-4484

Θεματικοί όροι: гидроксихлорохин, clinical manifestations, immunological disorders, therapy, hydroxychloroquine, клинические проявления, иммунологические нарушения, терапия

Περιγραφή αρχείου: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3484/2344; Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi:10.1038/nrdp.2016.39; Costenbader KH, Schur PH. We need better classification and terminology for “people at high risk of or in the process of developing lupus”. Arthritis Care Res (Hoboken). 2015;67(5):593-596. doi:10.1002/acr.22484; Lambers WM, Westra J, Bootsma H, de Leeuw K. From incomplete to complete systemic lupus erythematosus; A review of the predictive serological immune markers. Semin Arthritis Rheum. 2021;51(1):43-48. doi:10.1016/j.semarthrit.2020.11.006; Насонов ЕЛ, Попкова ТВ, Панафидина ТА. Проблемы ранней диагностики системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021;59(2):119-128. doi:10.47360/1995-4484-2021-119-128; Лила ВА, Мазуров ВИ, Лила АМ. «Неполная» системная красная волчанка в реальной клинической практике: трудности диагностики. Терапия. 2022;2(54):86-95. doi:10.18565/therapy.2022.2.86-95; Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526-1533. doi:10.1056/NEJMoa021933; Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapää-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther. 2011;13(1):R30. doi:10.1186/ar3258; Lambers WM, Westra J, Jonkman MF, Bootsma H, de Leeuw K. Incomplete systemic lupus erythematosus: What remains after application of American College of Rheumatology and Systemic Lupus International Collaborating Clinics criteria? Arthritis Care Res (Hoboken). 2020;72(5):607-614. doi:10.1002/acr.23894; Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-1277. doi:10.1002/art.1780251101; Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi:10.1002/art.1780400928; Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi:10.1002/art.34473; Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29:288-291.; Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus international comparison. J Rheumatol. 2000;27(2):373-376.; Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x; Sciascia S, Roccatello D, Radin M, Parodis I, Yazdany J, Pons-Estel G, et al. Differentiating between UCTD and early-stage SLE: From definitions to clinical approach. Nat Rev Rheumatol. 2022;18(1):9-21. doi:10.1038/s41584-021-00710-2; Greer JM, Panush RS. Incomplete lupus erythematosus. Arch Intern Med. 1989;149(11):2473-2476.; Swaak AJ, van de Brink H, Smeenk RJ, Manger K, Kalden JR, Tosi S, et al.; Study group on incomplete SLE and SLE with disease duration longer than 10 years. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford). 2001;40(1):89-94. doi:10.1093/rheumatology/40.1.89; Stahl-Hallengren CS, Nived O, Sturfelt G. Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus. 2004;13(2):85-88. doi:10.1191/0961203304lu477oa; Laustrup H, Voss A, Green A, Junker P. SLE disease patterns in a Danish population-based lupus cohort: an 8-year prospective study. Lupus. 2010;19(3):239-246. doi:10.1177/0961203309351033; Olsen NJ, Li QZ, Quan J, Wang L, Mutwally A, Karp DR. Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res Ther. 2012;14(4):R174. doi:10.1186/ar3927; Calvo-Alen J, Alarcon GS, Burgard SL, Burst N, Bartolucci AA, Williams HJ. Systemic lupus erythematosus: predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: multivariate analyses and identification of risk factors. J Rheumatol. 1996;23(3):469-475.; Mosca M, Tavoni A, Neri R, Bencivelli W, Bombardieri S. Undifferentiated connective tissue diseases: The clinical and serological profiles of 91 patients followed for at least 1 year. Lupus. 1998;7(2):95-100. doi:10.1191/096120398678919787; Danieli MG, Fraticelli P, Salvi A, Gabrielli A, Danieli G. Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. Clin Rheumatol. 1998;17(3):195-201. doi:10.1007/BF01451046; Danieli MG, Fraticelli P, Franceschini F, Cattaneo R, Farsi A, Passaleva A, et al. Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases. Clin Exp Rheumatol. 1999;17(5):585-591.; Williams HJ, Alarcon GS, Joks R, Steen VD, Bulpitt K, Clegg DO, et al. Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol. 1999;26(4):816-825.; Cavazzana I, Franceschini F, Belfiore N, Quinzanini M, Caporali R, Calzavara-Pinton P, et al. Undifferentiated connective tissue disease with antibodies to Ro/SSa: Clinical features and follow-up of 148 patients. Clin Exp Rheumatol. 2001;19(4):403-409.; Bodolay E, Csiki Z, Szekanecz Z, Ben T, Kiss E, Zeher M, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol. 2003;21(3):313-320.; Guerrero LF, Rueda JC, Arciniegas R, Rueda JM. Undifferentiated connective tissue disease in a heumatology center in Cali, Colombia: Clinical features of 94 patients followed for a year. Rheumatol Int. 2013;33(4):1085-1088. doi:10.1007/s00296-011-2234-y; García-González M, Rodríguez-Lozano B, Bustabad S, Ferraz-Amaro I. Undifferentiated connective tissue disease: Predictors of evolution into definite disease. Clin Exp Rheumatol. 2017;35(5):739-745.; Bortoluzzi A, Furini F, Campanaro F, Govoni M. Application of SLICC classification criteria in undifferentiated connective tissue disease and evolution in systemic lupus erythematosus: Analysis of a large monocentric cohort with a long-term follow-up. Lupus. 2017;26(6):616-622. doi:10.1177/0961203316671814; Zucchi D, Tani C, Monacci F, Elefante E, Carli L, Parma A, et al. Pregnancy and undifferentiated connective tissue disease: Outcome and risk of flare in 100 pregnancies. Rheumatology (Oxford). 2020;59(6):1335-1339. doi:10.1093/rheumatology/kez440; Ganczarczyk L, Urowitz MB, Gladman DD. “Latent lupus”. J Rheumatol. 1989;16(4):475-478.; Al Daabil M, Massarotti EM, Fine A, Tsao H, Ho P, Schur PH, et al. Development of SLE among “potential SLE” patients seen in consultation: Long-term follow-up. Int J Clin Pract. 2014;68(12):1508-1513. doi:10.1111/ijcp.12466; Tiao J, Feng R, Carr K, Okawa J, Werth VP. Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE). J Am Acad Dermatol. 2016;74(5):862-869. doi:10.1016/j.jaad.2015.12.029; Md Yusof MY, Psarras A, El-Sherbiny YM, Hensor EMA, Dutton K, Ul-Hassan S, et al. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis. 2018;77(10):1432-1439. doi:10.1136/annrheumdis-2018-213386; Ramsey-Goldman R, Alexander RV, Massarotti EM, Wallace DJ, Narain S, Arriens C, et al. Complement activation in patients with probable systemic lupus erythematosus and ability to predict progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020;72(1):78-88. doi:10.1002/art.41093; Sternhagen E, Bettendorf B, Lenert A, Lenert PS. The role of clinical features and serum biomarkers in identifying patients with incomplete lupus erythematosus at higher risk of transitioning to systemic lupus erythematosus: Current perspectives. J Inflamm Res. 2022;15:1133-1145. doi:10.2147/JIR.S275043; Chen Z, Li MT, Xu D, Leng XM, Wang Q, Tian XP, et al. Organ damage in patients with incomplete lupus syndromes: From a Chinese academic center. Clin Rheumatol. 2015;34(8):1383-1389. doi:10.1007/s10067-015-2884-3; Calvo-Alén J, Bastian HM, Straaton KV, Burgard SL, Mikhail IS, Alarcón GS. Identification of patient subsets among those presumptively diagnosed with, referred, and/or followed up for systemic lupus erythematosus at a large tertiary care center. Arthritis Rheum. 1995;38:1475-1484. doi:10.1002/art.1780381014; Vilá LM, Mayor AM, Valentin AH, Garcia-Soberal M, Vila S. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus. 2000;9:110-115. doi:10.1191/096120300678828073; Rúa-Figueroa Í, Richi P, López-Longo FJ, Galindo M, Calvo-Alén J, Olivé-Marqués A, et al.; EAS-SER (Systemic Diseases Study Group of the Spanish Society of Rheumatology). Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences. Medicine (Baltimore). 2015;94(1):e267. doi:10.1097/MD.0000000000000267; Olsen NJ, McAloose C, Carter J, Han BK, Raman I, Li QZ, et al. Clinical and immunologic profiles in incomplete lupus erythematosus and improvement with hydroxychloroquine treatment. Autoimmune Dis. 2016;2016:8791629. doi:10.1155/2016/8791629; Aberle T, Bourn RL, Munroe ME, Chen H, Roberts VC, Guthridge JM, et al. Clinical and serologic features in patients with incomplete lupus classification versus systemic lupus erythematosus patients and controls. Arthritis Care Res (Hoboken). 2017;69(12):1780-1788. doi:10.1002/acr.23201; Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, 2019 European League Against Rheumatism/ American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151-1159. doi:10.1136/annrheumdis-2018-214819; Aringer M, Johnson SR. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology (Oxford). 2020;59(Suppl 5):4-11. doi:10.1093/rheumatology/keaa379; Соловьев СК, Асеева ЕА, Попкова ТВ, Лила АМ, Мазуров ВИ, Насонов ЕЛ. Системная красная волчанка: Новые горизонты диагностики и терапии. Научно-практическая ревматология. 2020;58(1):5-14. doi:10.14412/1995-4484-2020-5-14; Radin M, Schreiber K, Cecchi I, Bortoluzzi A, Crisafulli F, de Freitas CM, et al. Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for systemic lupus erythematosus in a multicenter cohort study of 133 women with undifferentiated connective tissue disease. Arthritis Care Res (Hoboken). 2021;73(12):1804-1808. doi:10.1002/acr.24391; Насонов ЕЛ, Соловьев СК, Аршинов АВ. Системная красная волчанка: История и современность. Научно-практическая ревматология. 2022;60(4):397-412. doi:10.47360/1995-4484-2022-397-412; Barturen G, Babaei S, Català-Moll F, Martínez-Bueno M, Makowska Z, Martorell-Marugán J, et al. Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. Arthritis Rheumatol. 2021;73(6):1073-1085. doi:10.1002/art.41610; Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. doi:10.47360/1995-4484-2021-367-383; Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF. Association of serum B cell activating factor from the tumor necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus. 2013;22(9):873-884. doi:10.1177/0961203313496302; Suso JP, Posso-Osorio I, Jiménez CA, Naranjo-Escobar J, Ospina FE, Sánchez A, et al. Profile of BAFF and its receptors’ expression in lupus nephritis is associated with pathological classes. Lupus. 2018;27(5):708-715. doi:10.1177/0961203317739132; Slight-Webb S, Smith M, Bylinska A, Macwana S, Guthridge C, Lu R, et al. Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype. J Allergy Clin Immunol. 2020;146(6):1419-1433. doi:10.1016/j.jaci.2020.04.047; Munroe ME, Young KA, Kamen DL, Guthridge JM, Niewold TB, Costenbader KH, et al. Discerning risk of disease transition in relatives of systemic lupus erythematosus patients utilizing soluble mediators and clinical features. Arthritis Rheumatol. 2017;69(3):630-642. doi:10.1002/art.40004; Li QZ, Zhou J, Lian Y, Zhang B, Branch VK, Carr-Johnson F, et al. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin Exp Immunol. 2010;159(3):281-291. doi:10.1111/j.1365-2249.2009.04057.x; Munroe ME, Lu R, Zhao YD, Fife DA, Robertson JM, Guthridge JM, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. 2016;75(11):2014-2021. doi:10.1136/annrheumdis-2015-208140; Bourn R, James JA. Preclinical lupus. Curr Opin Rheumatol. 2015;27:433-439. doi:10.1097/BOR.0000000000000199; Olsen NJ, James JA, Arriens C, Ishimori ML, Wallace DJ, Kamen DL, et al. Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): Study protocol for a randomized controlled trial. Trials. 2018;19(1):694. doi:10.1186/s13063-018-3076-7; James JA, Kim-Howard XR, Bruner BF, Jonsson MK, McClain MT, Arbuckle MR, Walker C, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007;16(6):401-409. doi:10.1177/0961203307078579; Lambers WM, Westra J, Bootsma H, de Leeuw K. Hydroxychloroquine suppresses interferon-inducible genes and B cell activating factor in patients with incomplete and new-onset systemic lupus erythematosus. J Rheumatol. 2021;48(6):847-851. doi:10.3899/jrheum.200726; Durcan L, Petri M. Immunomodulators in SLE: Clinical evidence and immunologic actions. J Autoimmun. 2016;74:73-84. doi:10.1016/j.jaut.2016.06.010; Arnaud L, Mathian A, Devilliers H, Ruffatti A, Tektonidou M, Forastiero R, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015;14(3):192-200. doi:10.1016/j.autrev.2014.10.019; Решетняк ТМ, Кошелева НМ, Насонов ЕЛ. Системная красная волчанка и беременность: до, во время гестации и после родов. Научно-практическая ревматология. 2023;61(3):292-297. doi:10.47360/1995-4484-2023-292-297

Διαθεσιμότητα: https://rsp.mediar-press.net/rsp/article/view/3484
https://doi.org/10.47360/1995-4484-2023-678-688

View record from BASE

4

Academic Journal

Clinical and immunologic abnormalities in COVID-19 ; Клинико-иммунологические нарушения при COVID-19

Συγγραφείς: A. K. Karibova, S. S. Akhmedkhanov, M. T. Kudae, H. M. Malaev, А. К. Карибова, С. Ш. Ахмедханов, М. Т. Кудаев, Х. М. Малаев

Συνεισφορές: The article was created as part of the state assignment on topic №1021051403074-2. The investigation has not been sponsored. There are no conflicts of interest., Статья подготовлена в рамках государственного задания по теме №1021051403074-2. Исследование не имело спонсорской поддержки.

Πηγή: Modern Rheumatology Journal; Том 18, № 5 (2024); 90-94 ; Современная ревматология; Том 18, № 5 (2024); 90-94 ; 2310-158X ; 1996-7012

Θεματικοί όροι: аутоантитела при коронавирусной инфекции, immunological disorders in COVID-19, SARS-CoV-2, autoantibodies in coronavirus infection, иммунологические нарушения при COVID-19, SARS-CоV-2

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1644/1523; Habibi MA, Nezhad SF, Rajaei T, et al. Immunopathogenesis of viral infections in neurological autoimmune disease. BMC Neurol. 2023 May 23;23(1):201. doi:10.1186/s12883-023-03239-x.; Sundaresan B, Shirafkan F, Ripperger K, et al. The Role of Viral Infections in the Onset of Autoimmune Diseases. Viruses. 2023 Mar 18; 15(3):782. doi:10.3390/v15030782.; Lucia N, Francesca M, Maria DS, et al. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 – A systematic review of the literature. J Autoimmun. 2021 Feb:117:102592. doi:10.1016/j.jaut.2020.102592. Epub 2020 Dec 14.; Taussig D, Wine Y. Autoimmune Disease: When a virus lies in wait. Elife. 2021 Aug 4:10: e71121. doi:10.7554/eLife.71121.; Zhou SY, Zhang C, Shu WJ, et al. Emerging Roles of Coronavirus in Autoimmune Diseases. Arch Med Res. 2021 Oct;52(7): 665-672. doi:10.1016/j.arcmed.2021.03.012.; Damoiseaux J, Dotan A, Marvin J, et al. Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmun Rev. 2022 Mar;21(3):103012. doi:10.1016/j.autrev.2021.103012. Epub 2021 Dec 9.; Rivera-Correa J, Rodriguez A. Autoantibodies during infectious diseases: Lessons from malaria applied to COVID-19 and other infections. Front Immunol. 2022 Sep 15:13: 938011. doi:10.3389/fimmu.2022.938011. eCollection 2022.; Sherwani S, Ahmed KM, Suliman AM. Autoantibodies in Viral Infections. IntechOpen. 2019. 216 p.; Ehrenfeld M, Tincani A, Andreoli LV, et al. Covid-19 and autoimmunity. Autoimmun Rev. 2020 Aug;19(8):102-117. doi:10.1016/j.autrev.2020.102597.; Durigutto P, Grossi C, Borghi MO, et al. New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats. Haematologica. 2019 Apr;104(4):819-826. doi:10.3324/haematol. 2018.198119.; Полушин ЮС, Гаврилова ЕГ, Шлык ИВ и др. Катастрофический антифосфолипидный синдром при COVID-19. Вестник анестезиологии и реаниматологии. 2021; 18(1):17-26.; Berger J, Volc S. Autoantibodies in Covid-19 – a model for viral induced autoimmunity. J Eur Acad Dermatol Venereol. 2021 Sep;35(9):571-573. doi:10.1111/jdv.17396.; Zuo Y, Estes SK, Ali RA, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020 Nov 18;12(570):eabd3876. doi:10.1126/scitranslmed.abd3876. Epub 2020 Nov 2.; Park SH, Suh JW, Yang KS, et al. Clinical significance of antinuclear antibody positivity in patients with severe coronavirus disease 2019. Korean J Intern Med. 2023 May;38(3):417-426. doi:10.3904/kjim.2022.352.; Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021 Mar;33(2):155-162. doi:10.1097/BOR.0000000000000776.; Vahabi M, Mirsharif ES, Ghazanfari T. Is COVID-19 severity unrelated to antinuclear antibodies? Transpl Immunol. 2023 Jun:78: 101791. doi:10.1016/j.trim.2023.101791. Epub 2023 Jan 20.; Pascolini S, Vannini A, Deleonardi G, et al. COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful? Clin Transl Sci. 2021 Mar;14(2):502-508. doi:10.1111/cts.12908.; Каленчиц ТИ, Кабак СЛ, Кореневская ИB. Аутоантитела при коронавирусной инфекции (COVID-19): клиническое наблюдение. Научно-практическая ревматология. 2022;60(3):271-275.; Bossuyt X, Vulsteke JB, Van Elslande J, et al. Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13). Autoimmun Rev. 2023 Apr;22(4):103-112. doi:10.1016/j.autrev.2023.103288.; Zhang W, Tao Y, Zhu Y, at al. Effect of serum autoantibodies on the COVID-19 patient's prognosis. Front Microbiol. 2023 Nov 30;14:127-134. doi:10.3389/fmicb.2023.1259960.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1644
https://doi.org/10.14412/1996-7012-2024-5-90-94

View record from BASE

5

Academic Journal

Analyses of immune disturbances in children afflicted with purulent sinusitis ; Анализ иммунных нарушений у детей с гнойным синуитом ; Аналіз імунологічних розладів у дітей, хворих на гнійний синуїт

Συγγραφείς: Левицька, С.

Πηγή: Bukovinian Medical Herald; Vol. 14 No. 4 (56) (2010); 58-62 ; Буковинский медицинский вестник; Том 14 № 4 (56) (2010); 58-62 ; Буковинський медичний вісник; Том 14 № 4 (56) (2010); 58-62 ; 2413-0737 ; 1684-7903

Θεματικοί όροι: гнійний синуїт, діти, імунологічні розлади, гнойный синуит, дети, иммунологические нарушения, purulent sinusitis, children, immune disturbances

Περιγραφή αρχείου: application/pdf

Relation: http://e-bmv.bsmu.edu.ua/article/view/241816/239851

Διαθεσιμότητα: http://e-bmv.bsmu.edu.ua/article/view/241816

View record from BASE

6

Academic Journal

Analyses of immune disturbances in children afflicted with purulent sinusitis

Πηγή: Bukovinian Medical Herald; Vol. 14 No. 4 (56) (2010); 58-62
Буковинский медицинский вестник; Том 14 № 4 (56) (2010); 58-62
Буковинський медичний вісник; Том 14 № 4 (56) (2010); 58-62

Θεματικοί όροι: гнойный синуит, дети, иммунологические нарушения, purulent sinusitis, children, immune disturbances, гнійний синуїт, діти, імунологічні розлади, 3. Good health

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://e-bmv.bsmu.edu.ua/article/view/241816

View record at OpenAIRE

7

Academic Journal

ON THE ROLE OF IMMUNOLOGICAL ABNORMALITIES IN THE PATHOGENESIS OF COGNITIVE DYSFUNCTION IN MAJOR DEPRESSIVE DISORDER

Συγγραφείς: Roman Aleksandrovich Bekker, Yuriy Vitalevich Bykov

Πηγή: В мире научных открытий, Vol 0, Iss 8, Pp 40-62 (2016)

Θεματικοί όροι: депрессивные состояния, когнитивные нарушения, иммунологические нарушения, тимэктомия, спленэктомия, тималин, тактивин, тимоген, спленин, деринат, прополис, дибазол, левамизол, Agriculture, Science

Περιγραφή αρχείου: electronic resource

Relation: http://journal-s.org/index.php/vmno/article/view/9297; https://doaj.org/toc/2072-0831; https://doaj.org/toc/2307-9428

Σύνδεσμος πρόσβασης: https://doaj.org/article/564079d0f76b431d958d95aec6fa897d

View record in DOAJ Full Text Finder

8

Academic Journal

Роль хронічного стресу, реактивної та особистісної тривожності і деяких нейроендокринних, метаболічних та імунологічних порушень у патогенезі акне

Συγγραφείς: Dashko, М.О., Syzon, О.О.

Πηγή: Ukrainian Journal of Dermatology, Venerology, Cosmetology; № 2 (2019); 7-17
Украинский журнал дерматологии, венерологии, косметологии; № 2 (2019); 7-17
Український журнал дерматології, венерології, косметології; № 2 (2019); 7-17

Θεματικοί όροι: acne, stress, anxiety, neuroendocrine, metabolic, immunological disorders, акне, стрес, тривожність, нейроендокринні, метаболічні, імунологічні порушення, стресс, тревожность, нейроэндокринные, метаболические, иммунологические нарушения, 3. Good health